Amanote Research
Register
Sign In
Interest of the Association Azacitidine–lenalidomide as Frontline Therapy in High-Risk Myelodysplasia or Acute Myeloid Leukemia With Complex Karyotype
Leukemia
- United Kingdom
doi 10.1038/leu.2011.284
Full Text
Open PDF
Abstract
Available in
full text
Categories
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Date
October 14, 2011
Authors
E Scherman
S Malak
C Perot
N C Gorin
M T Rubio
F Isnard
Publisher
Springer Science and Business Media LLC
Related search
Therapy-Related Myelodysplasia and Acute Myeloid Leukemia
Seminars in Oncology
Oncology
Hematology
Azacitidine and Lenalidomide as an Alternative Treatment for Refractory Acute Myeloid Leukemia: A Case Report
Sao Paulo Medical Journal
Medicine
Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia
Clinical Lymphoma, Myeloma and Leukemia
Cancer Research
Oncology
Hematology
Evaluation of Azacitidine in Patients With Transplant‑ineligible Myelodysplastic Syndromes and Acute Myeloid Leukemia With Myelodysplasia‑related Changes in a Japanese Clinical Setting
Oncology Letters
Cancer Research
Oncology
Successful Treatment of Behçet's Disease Associated With Acute Myeloid Leukemia With Myelodysplasia-Related Changes Using Azacitidine and Tacrolimus Before Allogeneic Hematopoietic Stem Cell Transplantation
Internal Medicine
Internal Medicine
Medicine
Clofarabine, Idarubicin, and Cytarabine (CIA) as Frontline Therapy for Patients <= 60 Years With Newly Diagnosed Acute Myeloid Leukemia (AML)
Blood
Biochemistry
Immunology
Cell Biology
Hematology
Causality of Myelodysplasia and Acute Myeloid Leukemia and Their Genetic Abnormalities
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
“Epigenetic” Modification as Therapy for Acute Myeloid Leukemia
Cancer
Cancer Research
Oncology
Therapy of Acute Myeloid Leukemia
